PMC:7650537 / 23183-23427 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T115","span":{"begin":138,"end":146},"obj":"Disease"}],"attributes":[{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":". For all other 99 archived samples, a random pattern of rare, isolated reactivity was demonstrated, and none was confirmed as possessing SARS-CoV-2-neutralizing antibodies by PRNT (Figure 2 and Figure S1). Potential cross-reactivity with the H"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T187","span":{"begin":37,"end":38},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T188","span":{"begin":202,"end":204},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"}],"text":". For all other 99 archived samples, a random pattern of rare, isolated reactivity was demonstrated, and none was confirmed as possessing SARS-CoV-2-neutralizing antibodies by PRNT (Figure 2 and Figure S1). Potential cross-reactivity with the H"}

{"project":"LitCovid-sentences","denotations":[{"id":"T181","span":{"begin":2,"end":206},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":". For all other 99 archived samples, a random pattern of rare, isolated reactivity was demonstrated, and none was confirmed as possessing SARS-CoV-2-neutralizing antibodies by PRNT (Figure 2 and Figure S1). Potential cross-reactivity with the H"}

{"project":"LitCovid-PubTator","denotations":[{"id":"405","span":{"begin":138,"end":148},"obj":"Species"}],"attributes":[{"id":"A405","pred":"tao:has_database_id","subj":"405","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":". For all other 99 archived samples, a random pattern of rare, isolated reactivity was demonstrated, and none was confirmed as possessing SARS-CoV-2-neutralizing antibodies by PRNT (Figure 2 and Figure S1). Potential cross-reactivity with the H"}